{"id":"interferon-beta-type-1a","safety":{"commonSideEffects":[{"rate":"approximately 80%","effect":"Injection site reactions"},{"rate":"approximately 60%","effect":"Flu-like symptoms (fever, chills, myalgia)"},{"rate":"approximately 50%","effect":"Headache"},{"rate":"approximately 40%","effect":"Fatigue"},{"rate":"approximately 25%","effect":"Depression"},{"rate":"approximately 20%","effect":"Elevated liver enzymes"},{"rate":"approximately 15%","effect":"Leukopenia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Interferon beta-1a is a recombinant cytokine that activates type I interferon signaling pathways, leading to upregulation of anti-inflammatory genes and downregulation of pro-inflammatory cytokines. It reduces the migration of immune cells across the blood-brain barrier and decreases the activation of autoreactive T cells, thereby reducing demyelinating lesions and disease progression in multiple sclerosis.","oneSentence":"Interferon beta-1a binds to type I interferon receptors on immune cells to enhance antiviral and immunomodulatory responses, reducing inflammation and immune cell infiltration into the central nervous system.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:48:39.019Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsing-remitting multiple sclerosis"},{"name":"Clinically isolated syndrome with MRI features consistent with multiple sclerosis"}]},"trialDetails":[{"nctId":"NCT03958877","phase":"PHASE3","title":"A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Biogen","startDate":"2019-10-18","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":152},{"nctId":"NCT02937285","phase":"PHASE3","title":"National Multicenter, Controlled, Single-blind Study With Two Parallel Groups Evaluating the Safety and Efficacy of Sequential Treatment With Mitoxantrone and Interferon Versus Interferon Alone in Patients With Strong Risk of Progression in the Initial Phase of Multiple Sclerosis","status":"COMPLETED","sponsor":"Rennes University Hospital","startDate":"2010-12-06","conditions":"Multiple Sclerosis","enrollment":35},{"nctId":"NCT02727907","phase":"PHASE2, PHASE3","title":"Study of Efficacy and Safety of Drugs BCD-033 and Rebif for Treatment of Patients With Multiple Sclerosis","status":"COMPLETED","sponsor":"Biocad","startDate":"2015-02-12","conditions":"Multiple Sclerosis","enrollment":163},{"nctId":"NCT03570359","phase":"PHASE2","title":"A Study to Test a Potential New Treatment for COPD Patients Suffering From the Common Cold or Influenza","status":"COMPLETED","sponsor":"Synairgen Research Ltd.","startDate":"2018-01-29","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":122},{"nctId":"NCT00246324","phase":"PHASE4","title":"Safety and Efficacy Study of Doxycycline in Combination With Interferon-B-1a to Treat Multiple Sclerosis","status":"COMPLETED","sponsor":"Louisiana State University Health Sciences Center Shreveport","startDate":"2003-12","conditions":"Multiple Sclerosis","enrollment":16},{"nctId":"NCT05024006","phase":"NA","title":"Public Health Emergency: SOLIDARITY TRIAL Philippines","status":"COMPLETED","sponsor":"University of the Philippines","startDate":"2020-04-23","conditions":"Covid19","enrollment":1314},{"nctId":"NCT04032171","phase":"PHASE3","title":"Study of Evobrutinib in Participants With RMS","status":"TERMINATED","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2019-09-10","conditions":"Relapsing-remitting Multiple Sclerosis","enrollment":1},{"nctId":"NCT04032158","phase":"PHASE3","title":"Study of Evobrutinib in Participants With Relapsing Multiple Sclerosis (RMS)","status":"TERMINATED","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2019-08-26","conditions":"Relapsing-remitting Multiple Sclerosis","enrollment":3},{"nctId":"NCT03177083","phase":"PHASE4","title":"Evaluate Safety/Tolerability in Portuguese Participants With RRMS Transitioning From Current Therapy","status":"COMPLETED","sponsor":"Biogen","startDate":"2017-01-30","conditions":"Relapsing Remitting Multiple Sclerosis","enrollment":80},{"nctId":"NCT04521400","phase":"PHASE2","title":"the Investigation Into Beneficial Effects of High-dose Interferon Beta 1-a, Compared to Low-dose Interferon Beta 1-a in Moderate to Severe Covid-19","status":"UNKNOWN","sponsor":"Shahid Beheshti University of Medical Sciences","startDate":"2020-08-20","conditions":"Covid19","enrollment":100},{"nctId":"NCT04343768","phase":"PHASE2","title":"An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b And The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized Clinical Trial","status":"COMPLETED","sponsor":"Shahid Beheshti University of Medical Sciences","startDate":"2020-04-09","conditions":"COVID-19","enrollment":60},{"nctId":"NCT04350671","phase":"PHASE4","title":"Interferon Beta 1a in Hospitalized COVID-19 Patients","status":"UNKNOWN","sponsor":"Shahid Beheshti University of Medical Sciences","startDate":"2020-04-15","conditions":"COVID-19","enrollment":40},{"nctId":"NCT04289675","phase":"","title":"Multiple Sclerosis: Chi3L1 and Treatment Efficacy","status":"COMPLETED","sponsor":"Central Hospital, Nancy, France","startDate":"2012-01-01","conditions":"Multiple Sclerosis","enrollment":63},{"nctId":"NCT01514370","phase":"PHASE2","title":"Dietary Supplement of Curcumin in Subjects With Active Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta 1a","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2012-04-30","conditions":"Multiple Sclerosis","enrollment":80},{"nctId":"NCT02064816","phase":"PHASE4","title":"A Study of Rebif® in Subjects With Relapsing Multiple Sclerosis","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2014-05-31","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":200},{"nctId":"NCT00037102","phase":"PHASE4","title":"Combination Therapy With Avonex and BiMonthly High Dose Intravenous Methotrexate in Multiple Sclerosis","status":"COMPLETED","sponsor":"MidAmerica Neuroscience Research Foundation at Rowe Neurology Institute","startDate":"2001-07","conditions":"Multiple Sclerosis","enrollment":16},{"nctId":"NCT00037115","phase":"PHASE4","title":"Induction Therapy With a Single High Dose Bolus of Intravenous Methotrexate With Leucovorin Rescue, Prior to Initiation of AVONEX® Treatment, in Patients Presenting With a First Acute Demyelinating Event.","status":"WITHDRAWN","sponsor":"MidAmerica Neuroscience Research Foundation at Rowe Neurology Institute","startDate":"2002-05","conditions":"Demyelinating Disorders, Multiple Sclerosis, Optic Neuritis","enrollment":""},{"nctId":"NCT00179478","phase":"PHASE4","title":"Long Term Study of Avonex Therapy Following a First Attack of Multiple Sclerosis","status":"COMPLETED","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2001-02","conditions":"Multiple Sclerosis, Optic Neuritis, Transverse Myelitis","enrollment":155},{"nctId":"NCT00097318","phase":"PHASE1","title":"Safety Study of Interferon Beta 1a to for Acute Stroke","status":"COMPLETED","sponsor":"National Institute of Neurological Disorders and Stroke (NINDS)","startDate":"2004-11-17","conditions":"Cerebrovascular Accident","enrollment":60},{"nctId":"NCT00548405","phase":"PHASE3","title":"Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2007-10","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":840},{"nctId":"NCT02359877","phase":"PHASE1","title":"Open Label Study of Tolerability, Pharmacokinetics and Pharmacodynamics of BCD-054 (Pegylated Interferon Beta-1a), IM and SC, Compared to Rebif® and Avonex® in Healthy Volunteers","status":"COMPLETED","sponsor":"Biocad","startDate":"2014-07","conditions":"Healthy","enrollment":60},{"nctId":"NCT01064401","phase":"PHASE3","title":"Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis","status":"COMPLETED","sponsor":"Biogen","startDate":"2010-05","conditions":"Relapsing-Remitting Multiple Sclerosis","enrollment":1841},{"nctId":"NCT02364986","phase":"PHASE1","title":"Immune- and miRNA-response to Recombinant Interferon Beta in Healthy Volunteers and Patients With Relapsing Remitting Multiple Sclerosis","status":"UNKNOWN","sponsor":"PD Dr. Marcus Müller","startDate":"2015-01","conditions":"Relapsing-remitting Multiple Sclerosis","enrollment":50},{"nctId":"NCT01714089","phase":"PHASE2","title":"Proof of Concept Study Evaluating RNS60 in the Treatment of Relapsing Remitting Multiple Sclerosis","status":"WITHDRAWN","sponsor":"Revalesio Corporation","startDate":"","conditions":"Relapsing Remitting Multiple Sclerosis","enrollment":""},{"nctId":"NCT01317004","phase":"PHASE4","title":"Patients With Relapse Remitting Multiple Sclerosis (RRMS): Candidates for MS Therapy Change","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-05","conditions":"Relapsing Remitting Multiple Sclerosis","enrollment":61},{"nctId":"NCT01207648","phase":"","title":"Retrospective Cohort Study of Rebif® Use in Pediatric Multiple Sclerosis (MS) Subjects (REPLAY)","status":"COMPLETED","sponsor":"EMD Serono","startDate":"2010-07","conditions":"Multiple Sclerosis","enrollment":307},{"nctId":"NCT01534182","phase":"PHASE4","title":"Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-01","conditions":"Relapsing Remitting Multiple Sclerosis","enrollment":298},{"nctId":"NCT01142453","phase":"","title":"An Observational Study Evaluating Therapy Optimisation Using High-frequency and High-dosage Administration of Interferon-beta (Rebif®) in Multiple Sclerosis (MS) Patients","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2005-05","conditions":"Relapsing-Remitting Multiple Sclerosis","enrollment":231},{"nctId":"NCT01142557","phase":"","title":"An Observational Study to Document the Effectiveness and Compatibility of Rebif 44 or 22 µg in the Therapy of the Chronic Multiple Sclerosis","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2004-06","conditions":"Multiple Sclerosis","enrollment":522},{"nctId":"NCT00501943","phase":"PHASE2","title":"Neuroprotection With Riluzole Patients With Early Multiple Sclerosis","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2006-07","conditions":"Multiple Sclerosis","enrollment":43},{"nctId":"NCT01142492","phase":"","title":"A Postmarketing Surveillance (PMS) Study to Evaluate the Extent to Which Patient Compliance is Influenced by Use of a Variable Titration Regimen at the Start of Treatment of Relapsing Multiple Sclerosis (MS) With Interferon Beta 1a (Rebif®)","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2005-01","conditions":"Relapsing-Remitting Multiple Sclerosis","enrollment":403},{"nctId":"NCT01142518","phase":"","title":"An Observational Study of Multiple Sclerosis (MS) Patients Starting or Restarting Baseline Treatment With Interferon Beta 1a After the Use of Escalation Treatment With Mitoxantrone","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2005-07","conditions":"Relapsing-Remitting Multiple Sclerosis","enrollment":86},{"nctId":"NCT00490906","phase":"","title":"Comparison of Bone Effects With Copaxone and Interferon in Multiple Sclerosis","status":"COMPLETED","sponsor":"Nancy Hammond, MD","startDate":"2007-06","conditions":"Multiple Sclerosis, Low Bone Density","enrollment":60},{"nctId":"NCT00287079","phase":"PHASE3","title":"A Prospective Study Looking at the Use of Rebif® in Subjects With Clinically Isolated Syndrome","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2005-10","conditions":"Clinically Isolated Syndrome","enrollment":35},{"nctId":"NCT01181115","phase":"PHASE3","title":"Avonex Safety and Tolerability in Chinese Subjects With Relapsing Multiple Sclerosis (MS)","status":"COMPLETED","sponsor":"Biogen","startDate":"2010-04","conditions":"Multiple Sclerosis","enrollment":60},{"nctId":"NCT01863069","phase":"PHASE1","title":"Avonex®: Safety, Blood Levels and Effects","status":"COMPLETED","sponsor":"Trio Medicines Ltd.","startDate":"2001-01","conditions":"Multiple Sclerosis (MS)","enrollment":77},{"nctId":"NCT00819000","phase":"","title":"Therapy Optimization in Multiple Sclerosis (MS)","status":"COMPLETED","sponsor":"Teva Neuroscience, Inc.","startDate":"2008-12","conditions":"Multiple Sclerosis","enrollment":2878},{"nctId":"NCT00618527","phase":"EARLY_PHASE1","title":"Combination Therapy Using Cellcept and Rebif in RRMS","status":"COMPLETED","sponsor":"Aaron Boster","startDate":"2006-08","conditions":"Multiple Sclerosis","enrollment":31},{"nctId":"NCT01126177","phase":"PHASE2","title":"Comparing Efficacy and Safety of Inhaled SNG001 to Placebo","status":"COMPLETED","sponsor":"Synairgen Research Ltd.","startDate":"2010-03","conditions":"Asthma","enrollment":300},{"nctId":"NCT00599274","phase":"","title":"Study to Determine if Avonex and Rebif Work Comparably Well in Subjects With Relapsing Multiple Sclerosis","status":"COMPLETED","sponsor":"Biogen","startDate":"2002-08","conditions":"Multiple Sclerosis","enrollment":136},{"nctId":"NCT00151801","phase":"PHASE2","title":"Safety and Tolerability of Interferon-Beta-1a and Estroprogestins Association in MS Patients","status":"UNKNOWN","sponsor":"S. Andrea Hospital","startDate":"2002-05","conditions":"Multiple Sclerosis","enrollment":200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Avonex"],"phase":"phase_3","status":"active","brandName":"Interferon beta type 1a","genericName":"Interferon beta type 1a","companyName":"Biogen","companyId":"biogen","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Interferon beta-1a binds to type I interferon receptors on immune cells to enhance antiviral and immunomodulatory responses, reducing inflammation and immune cell infiltration into the central nervous system. Used for Relapsing-remitting multiple sclerosis, Clinically isolated syndrome with MRI features consistent with multiple sclerosis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}